Welcome to Amarantus Therapeutics

Amarantus Therapeutics, Inc. (“Amarantus”) is focused on the discovery and early development of therapeutic proteins with the potential to address critically important biological pathways involved in the treatment human disease.

The Company’s lead program (AMRS001) is aimed at developing treatments to address the underlying Programmed Cell Death (Apoptosis) associated a wide range of devastating human disorders. With a global trend towards an increasing life expectancy and emerging countries gaining access to critical medical care, the development of Apoptosis-related treatments represents a significant market opportunity that addresses the critical unmet medical need of safely and effectively improving treatments for patients.

Amarantus business strategy, utilizing Amarantus’ seasoned Management Team, world-class Scientific Advisory Board and Board of Directors, is to employ our PhenoGuard Drug Discovery Engine to discover medically-relevant secreted human proteins, scientifically establish their therapeutic potential, develop pre-clinical and clinical programs to further their development, and advance them through successive de-risking milestones to maximize their commercial potential while making them attractive partnering targets for product development focused biotechnology, pharmaceutical and medical device companies. (Read more)